NEW YORK (GenomeWeb) – Cancer testing firm OncoCyte has announced its intention to commercialize its liquid biopsies using NanoString Technologies' nCounter platform.

The Alameda, California-based firm recently reported promising results from a study conducted on a lung cancer diagnostic test being developed in partnership with The Wistar Institue. The study showed that the assay, which was originally developed using microarray technology from Illumina, could successfully be transitioned to the NanoString nCounter platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.